Search

Your search keyword '"Babu, Sunil"' showing total 238 results
Start Over Author "Babu, Sunil"
238 results on '"Babu, Sunil"'

1. Outcomes in Patients With Poor-risk Cytogenetics With or Without TP53 Mutations Treated With Venetoclax and Azacitidine

Author

Pollyea, Daniel A, Pratz, Keith W, Wei, Andrew H, Pullarkat, Vinod, Jonas, Brian A, Recher, Christian, Babu, Sunil, Schuh, Andre C, Dail, Monique, Sun, Yan, Potluri, Jalaja, Chyla, Brenda, and DiNardo, Courtney D

Subjects
Cancer, Hematology, Clinical Research, Clinical Trials and Supportive Activities, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Humans, Antineoplastic Combined Chemotherapy Protocols, Azacitidine, Bridged Bicyclo Compounds, Heterocyclic, Cytogenetic Analysis, Leukemia, Myeloid, Acute, Mutation, Tumor Suppressor Protein p53, Treatment Outcome, Clinical Trials, Phase III as Topic, Clinical Trials, Phase I as Topic, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposeTo evaluate efficacy and safety of venetoclax + azacitidine in treatment-naïve patients with acute myeloid leukemia harboring poor-risk cytogenetics and TP53mut or TP53wt.Patients and methodsWe analyzed data from a phase III study (NCT02993523) comparing venetoclax (400 mg orally days 1-28) + azacitidine (75 mg/m2 days 1-7) or placebo + azacitidine, and from a phase Ib study (NCT02203773) of venetoclax + azacitidine. Patients were ineligible for intensive therapy. TP53 status was analyzed centrally; cytogenetic studies were performed locally.ResultsPatients (n = 127) with poor-risk cytogenetics receiving venetoclax + azacitidine (TP53wt = 50; TP53mut = 54) were compared with patients with poor-risk cytogenetics (n = 56) receiving azacitidine alone (TP53wt = 22; TP53mut = 18).For poor-risk cytogenetics + TP53wt patients, venetoclax + azacitidine versus azacitidine alone resulted in composite remission rates (CRc) of 70% versus 23%, median duration of remission (DoR) of 18.4 versus 8.5 months, and median overall survival (OS) of 23.4 versus 11.3 months, respectively. Outcomes with venetoclax + azacitidine were comparable with similarly treated patients with intermediate-risk cytogenetics and TP53wt.For poor-risk cytogenetics + TP53mut patients, venetoclax + azacitidine versus azacitidine alone resulted in CRc of 41% versus 17%, median DoR of 6.5 versus 6.7 months, and median OS of 5.2 versus 4.9 months, respectively.For poor-risk cytogenetics + TP53mut patients, predominant grade ≥3 adverse events (AE) for venetoclax + azacitidine versus azacitidine were febrile neutropenia (55%/39%), thrombocytopenia (28%/28%), neutropenia (26%/17%), anemia (13%/6%), and pneumonia (28%/33%). AEs were comparable between TP53mut and TP53wt patients.ConclusionsIn poor-risk cytogenetics + TP53mut patients, venetoclax + azacitidine improved remission rates but not DoR or OS compared with azacitidine alone. However, in poor-risk cytogenetics + TP53wt patients, venetoclax + azacitidine resulted in higher remission rates and longer DoR and OS than azacitidine alone, with outcomes comparable with similarly treated patients with intermediate-risk cytogenetics. Toxicities were similar in TP53mut and TP53wt patients. See related commentary by Green and Zeidner, p. 5235.

Published
2022

3. Impact of Exigent Research Network’s partnership with the Tempus AI TIME Program on the screening and matching of patients for clinical trials.

Author

Gajra, Ajeet, primary, Mallahan, Samantha, additional, Blau, Sibel, additional, Peguero, Julio Antonio, additional, Shoukier, Mahran, additional, Kanaan, Mohamad, additional, Huynh, Chanh Trung, additional, Efiom-Ekaha, Daniel N., additional, Vankayala, Hema M., additional, Kitchen, Kyle, additional, Kendall, Stephan Disean, additional, Orsini, James Michael, additional, Babu, Sunil, additional, Hellyer, Jessica, additional, Weart, Thomas, additional, Meyer, Janelle Marie, additional, Clifford, Christian, additional, Skelly, Danielle, additional, Patnaude, Emily, additional, and Cooney, Matthew M., additional

Published
2024
Full Text
View/download PDF

5. Long-Term Efficacy and Safety of the Long-Acting Complement C5 Inhibitor Ravulizumab for the Treatment of Atypical Hemolytic Uremic Syndrome in Adults

Author

Babu, Sunil, Broeders, Nilufer, Lietar, Nicole, Brown, Fiona, Campbell, Philip, Campistol, Josep M., Chowdhury, Paramit, Kasimatis, Theo, Cirami, Lino, Caroti, Leonardo, Antognoli, Guilia, Delmas, Yahsou, Dobronravov, Vladimir, Gaeckler, Anja, Garrouste, Cyril, Greenwood, Gregory, Griffin, Siân, Huang, Chiu-Ching, Chen, I-Ru, Huang, Susan, Kim, Jin Seok, La Manna, Gaetano, Le Quintrec, Moglie, Jeantet, Guillaume, Fumie, Iino, Rondeau, Eric, Haller, Hermann, Morelle, Johan, Goffin, Eric, Muhlfeld, Anja, Nagaraj, Shashi, Arepally, Gowthami, Oh, Doyeun, Okumi, Masayoshi, Terente, Manuel Praga, Provot, Francois, Schönermarck, Ulf, Fischereder, Michael, Terrada, Natalia Ramos, Seitz-Polski, Barbara, Favre, Guillaume, Boyer-Suavet, Sonia, Vinogradova, Maria, Kirsanova, Tatiana, Wong, Edwin K.S., Barbour, Thomas, Scully, Marie, Ariceta, Gema, Cataland, Spero, Garlo, Katherine, Heyne, Nils, Luque, Yosu, Menne, Jan, Miyakawa, Yoshitaka, Yoon, Sung-Soo, and Kavanagh, David

Published
2021
Full Text
View/download PDF

7. Safety and Efficacy of Nivolumab in Patients With Advanced Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study

Author

McFarlane, Joshua J., Kochenderfer, Mark D., Olsen, Mark R., Bauer, Todd M., Molina, Ana, Hauke, Ralph J., Reeves, James A., Babu, Sunil, Van Veldhuizen, Peter, Somer, Bradley, Gunuganti, Vijay, Schnadig, Ian, George, Saby, Page, Ray D., Arrowsmith, Edward, Jain, Rohit K., Zhang, Joshua, McHenry, M. Brent, Johansen, Jennifer L., and Vogelzang, Nicholas J.

Published
2020
Full Text
View/download PDF

8. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment

Author

Babu, Sunil, Broeders, Nilufer, Lietar, Nicole, Brown, Fiona, Campbell, Philip, Chowdhury, Paramit, Kasimatis, Theo, Cirami, Lino, Caroti, Leonardo, Antognoli, Guilia, Delmas, Yahsou, Dobronravov, Vladimir, Gaeckler, Anja, Garrouste, Cyril, Greenwood, Gregory, Griffin, Siân, Huang, Chiu-Ching, Chen, I-Ru, Huang, Susan, Kim, Jin Seok, La Manna, Gaetano, Comai, Giorgia, Cappuccilli, Maria, Le Quintrec, Moglie, Jeantet, Guillaume, Fumie, Iino, Luque, Yosu, Menne, Jan, Morelle, Johan, Goffin, Eric, Muhlfeld, Anja, Nagaraj, Shashi, Arepally, Gowthami, Oh, Doyeun, Okumi, Masayoshi, Terente, Manuel Praga, Gutierréz, Elena, Rodriguez, Paola, Provot, Francois, Schönermarck, Ulf, Fischereder, Michael, Terrada, Natalia Ramos, Seitz-Polski, Barbara, Favre, Guillaume, Boyer-Suavet, Sonia, Vinogradova, Maria, Kirsanova, Tatiana, Wong, Edwin K.S., Rondeau, Eric, Scully, Marie, Ariceta, Gema, Barbour, Tom, Cataland, Spero, Heyne, Nils, Miyakawa, Yoshitaka, Ortiz, Stephan, Swenson, Eugene, Vallee, Marc, Yoon, Sung-Soo, Kavanagh, David, and Haller, Hermann

Published
2020
Full Text
View/download PDF

9. 666 Safety, efficacy, and biomarker results of SRK-181, a latent TGFβ1 inhibitor, in anti-PD-1 resistant metastatic ccRCC patients

Author

Yap, Timothy, primary, Vaishampayan, Ulka N, additional, Kilari, Deepak, additional, Sweis, Randy, additional, Barve, Minal, additional, Gainor, Justin, additional, Tarhini, Ahmad A, additional, Karim, Raghad, additional, Sher, Amna, additional, Park, David, additional, Babu, Sunil, additional, McKay, Rana, additional, Ju, Yawen, additional, Liu, Lan, additional, Henry, Susan, additional, and Gan, Lu, additional

Published
2023
Full Text
View/download PDF

10. Safety, Efficacy, and Patient-Reported Health-Related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Non–Small Cell Lung Cancer, Including Patients Aged 70 Years or Older or with Poor Performance Status (CheckMate 153)

Author

Spigel, David R., McCleod, Michael, Jotte, Robert M., Einhorn, Lawrence, Horn, Leora, Waterhouse, David M., Creelan, Ben, Babu, Sunil, Leighl, Natasha B., Chandler, Jason C., Couture, Felix, Keogh, George, Goss, Glenwood, Daniel, Davey B., Garon, Edward B., Schwartzberg, Lee S., Sen, Rohini, Korytowsky, Beata, Li, Ang, Aanur, Nivedita, and Hussein, Maen A.

Published
2019
Full Text
View/download PDF

12. Data from Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax and Azacitidine

Author

Pollyea, Daniel A., primary, Pratz, Keith W., primary, Wei, Andrew H., primary, Pullarkat, Vinod, primary, Jonas, Brian A., primary, Recher, Christian, primary, Babu, Sunil, primary, Schuh, Andre C., primary, Dail, Monique, primary, Sun, Yan, primary, Potluri, Jalaja, primary, Chyla, Brenda, primary, and DiNardo, Courtney D., primary

Published
2023
Full Text
View/download PDF

13. Supplementary Figure from Phase Ib/II Study of Enzalutamide with Samotolisib (LY3023414) or Placebo in Patients with Metastatic Castration-Resistant Prostate Cancer

Author

Sweeney, Christopher J., primary, Percent, Ivor J., primary, Babu, Sunil, primary, Cultrera, Jennifer L., primary, Mehlhaff, Bryan A., primary, Goodman, Oscar B., primary, Morris, David S., primary, Schnadig, Ian D., primary, Albany, Costantine, primary, Shore, Neal D., primary, Sieber, Paul R., primary, Guba, Susan C., primary, Zhang, Wei, primary, Wacheck, Volker, primary, Donoho, Gregory P., primary, Szpurka, Anna M., primary, Callies, Sophie, primary, Lin, Boris Kin, primary, and Bendell, Johanna C., primary

Published
2023
Full Text
View/download PDF

14. Supplementary Data from Phase Ib/II Study of Enzalutamide with Samotolisib (LY3023414) or Placebo in Patients with Metastatic Castration-Resistant Prostate Cancer

Author

Sweeney, Christopher J., primary, Percent, Ivor J., primary, Babu, Sunil, primary, Cultrera, Jennifer L., primary, Mehlhaff, Bryan A., primary, Goodman, Oscar B., primary, Morris, David S., primary, Schnadig, Ian D., primary, Albany, Costantine, primary, Shore, Neal D., primary, Sieber, Paul R., primary, Guba, Susan C., primary, Zhang, Wei, primary, Wacheck, Volker, primary, Donoho, Gregory P., primary, Szpurka, Anna M., primary, Callies, Sophie, primary, Lin, Boris Kin, primary, and Bendell, Johanna C., primary

Published
2023
Full Text
View/download PDF

15. Abstract GS3-01: GS3-01 EMERALD phase 3 trial of elacestrant versus standard of care endocrine therapy in patients with ER+/HER2- metastatic breast cancer: Updated results by duration of prior CDK4/6i in metastatic setting

Author

Bardia, Aditya, primary, Bidard, Francois-Clement, additional, Neven, Patrick, additional, Streich, Guillermo, additional, Montero, Alberto J., additional, Forget, Frederic, additional, Mouret-Reynier, Marie-Ange, additional, Sohn, Joo Hyuk, additional, Taylor, Donatienne, additional, Harnden, Kathleen K., additional, Khong, Hung, additional, Kocsis, Judit, additional, Dalenc, Florence, additional, Dillon, Patrick, additional, Babu, Sunil, additional, Waters, Simon, additional, Deleu, Ines, additional, García-Sáenz, Jose Angel, additional, Bria, Emilio, additional, Cazzaniga, Marina Elena, additional, Aftimos, Philippe, additional, Cortés, Javier, additional, Tonini, Giulia, additional, Sahmoud, Tarek, additional, Habboubi, Nassir, additional, Grzegorzewski, Krzysztof, additional, and Kaklamani, Virginia, additional

Published
2023
Full Text
View/download PDF

16. RELATIVITY-123: A phase 3, randomized, open-label study of nivolumab (NIVO) + relatlimab (RELA) fixed-dose combination (FDC) versus regorafenib or trifluridine + tipiracil (TAS-102) in later-line metastatic colorectal cancer (mCRC).

Author

Feeney, Kynan, primary, Joubert, Warren Lance, additional, Bordoni, Rodolfo Eduardo, additional, Babu, Sunil, additional, Marimuthu, Sathiya, additional, Hipkin, Bill, additional, Huang, Liping, additional, Tam, Rachel, additional, and Acosta Rivera, Mirelis, additional

Published
2023
Full Text
View/download PDF

17. ELN Risk Stratification Is Not Predictive of Outcomes for Treatment-Naïve Patients with Acute Myeloid Leukemia Treated with Venetoclax and Azacitidine

Author

Döhner, Hartmut, primary, Pratz, Keith W., additional, DiNardo, Courtney D., additional, Jonas, Brian A., additional, Pullarkat, Vinod A., additional, Thirman, Michael J., additional, Recher, Christian, additional, Schuh, Andre C., additional, Babu, Sunil, additional, Dail, Monique, additional, Ku, Grace, additional, Sun, Yan, additional, Potluri, Jalaja, additional, Chyla, Brenda, additional, and Pollyea, Daniel A., additional

Published
2022
Full Text
View/download PDF

18. Mosunetuzumab Monotherapy Continues to Demonstrate Promising Efficacy and Durable Complete Responses in Elderly/Unfit Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

Author

Olszewski, Adam J., primary, Avigdor, Abraham, additional, Babu, Sunil, additional, Levi, Itai, additional, Eradat, Herbert, additional, Abadi, Uri, additional, Holmes, Houston, additional, McKinney, Matthew, additional, Woszczyk, Dariusz, additional, Giannopoulos, Krzysztof, additional, Jurczak, Wojciech, additional, Dunshee, Diana, additional, Yang, Annie, additional, Zhou, Mingzhu, additional, Qayum, Naseer, additional, Sellam, Gila, additional, and Horowitz, Netanel A., additional

Published
2022
Full Text
View/download PDF

19. Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial

Author

Bidard, Francois-Clement, primary, Kaklamani, Virginia G., additional, Neven, Patrick, additional, Streich, Guillermo, additional, Montero, Alberto J., additional, Forget, Frédéric, additional, Mouret-Reynier, Marie-Ange, additional, Sohn, Joo Hyuk, additional, Taylor, Donatienne, additional, Harnden, Kathleen K., additional, Khong, Hung, additional, Kocsis, Judit, additional, Dalenc, Florence, additional, Dillon, Patrick M., additional, Babu, Sunil, additional, Waters, Simon, additional, Deleu, Ines, additional, García Sáenz, José A., additional, Bria, Emilio, additional, Cazzaniga, Marina, additional, Lu, Janice, additional, Aftimos, Philippe, additional, Cortés, Javier, additional, Liu, Shubin, additional, Tonini, Giulia, additional, Laurent, Dirk, additional, Habboubi, Nassir, additional, Conlan, Maureen G., additional, and Bardia, Aditya, additional

Published
2022
Full Text
View/download PDF

20. Primary analysis from the phase 2 study of continuous talazoparib (TALA) plus intermittent low-dose temozolomide (TMZ) in patients with relapsed or refractory extensive-stage small cell lung cancer (ES-SCLC).

Author

Goldman, Jonathan W., primary, Cummings, Amy Lauren, additional, Mendenhall, Melody A., additional, Velez, Maria A, additional, Babu, Sunil, additional, Johnson, Tirrell T., additional, Alcantar, Juan M., additional, Dakhil, Shaker R., additional, Kanamori, David E., additional, Lawler, William E., additional, Anand, Sidharth, additional, Chauv, James, additional, Garon, Edward B., additional, and Slamon, Dennis J., additional

Published
2022
Full Text
View/download PDF

21. Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial.

Author

UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service d'oncologie médicale, Bidard, Francois-Clement, Kaklamani, Virginia G, Neven, Patrick, Streich, Guillermo, Montero, Alberto J, Forget, Frédéric, Mouret-Reynier, Marie-Ange, Sohn, Joo Hyuk, Taylor, Donatienne, Harnden, Kathleen K, Khong, Hung, Kocsis, Judit, Dalenc, Florence, Dillon, Patrick M, Babu, Sunil, Waters, Simon, Deleu, Ines, García Sáenz, José A, Bria, Emilio, Cazzaniga, Marina, Lu, Janice, Aftimos, Philippe, Cortés, Javier, Liu, Shubin, Tonini, Giulia, Laurent, Dirk, Habboubi, Nassir, Conlan, Maureen G, Bardia, Aditya, UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service d'oncologie médicale, Bidard, Francois-Clement, Kaklamani, Virginia G, Neven, Patrick, Streich, Guillermo, Montero, Alberto J, Forget, Frédéric, Mouret-Reynier, Marie-Ange, Sohn, Joo Hyuk, Taylor, Donatienne, Harnden, Kathleen K, Khong, Hung, Kocsis, Judit, Dalenc, Florence, Dillon, Patrick M, Babu, Sunil, Waters, Simon, Deleu, Ines, García Sáenz, José A, Bria, Emilio, Cazzaniga, Marina, Lu, Janice, Aftimos, Philippe, Cortés, Javier, Liu, Shubin, Tonini, Giulia, Laurent, Dirk, Habboubi, Nassir, Conlan, Maureen G, and Bardia, Aditya

Abstract

Patients with pretreated estrogen receptor (ER)-positive/human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer have poor prognosis. Elacestrant is a novel, oral selective ER degrader that demonstrated activity in early studies. This randomized, open-label, phase III trial enrolled patients with ER-positive/HER2-negative advanced breast cancer who had one-two lines of endocrine therapy, required pretreatment with a cyclin-dependent kinase 4/6 inhibitor, and ≤ 1 chemotherapy. Patients were randomly assigned to elacestrant 400 mg orally once daily or standard-of-care (SOC) endocrine monotherapy. Primary end points were progression-free survival (PFS) by blinded independent central review in all patients and patients with detectable mutations. Patients were randomly assigned to elacestrant (n = 239) or SOC (n = 238). mutation was detected in 47.8% of patients, and 43.4% received two prior endocrine therapies. PFS was prolonged in all patients (hazard ratio = 0.70; 95% CI, 0.55 to 0.88; = .002) and patients with mutation (hazard ratio = 0.55; 95% CI, 0.39 to 0.77; = .0005). Treatment-related grade 3/4 adverse events occurred in 7.2% receiving elacestrant and 3.1% receiving SOC. Treatment-related adverse events leading to treatment discontinuations were 3.4% in the elacestrant arm versus 0.9% in SOC. Nausea of any grade occurred in 35.0% receiving elacestrant and 18.8% receiving SOC (grade 3/4, 2.5% and 0.9%, respectively). Elacestrant is the first oral selective ER degrader demonstrating a significant PFS improvement versus SOC both in the overall population and in patients with mutations with manageable safety in a phase III trial for patients with ER-positive/HER2-negative advanced breast cancer.

Published
2022

22. Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial

Author

Bidard, F, Kaklamani, V, Neven, P, Streich, G, Montero, A, Forget, F, Mouret-Reynier, M, Sohn, J, Taylor, D, Harnden, K, Khong, H, Kocsis, J, Dalenc, F, Dillon, P, Babu, S, Waters, S, Deleu, I, García Sáenz, J, Bria, E, Cazzaniga, M, Lu, J, Aftimos, P, Cortés, J, Liu, S, Tonini, G, Laurent, D, Habboubi, N, Conlan, M, Bardia, A, Bidard, Francois-Clement, Kaklamani, Virginia G, Neven, Patrick, Streich, Guillermo, Montero, Alberto J, Forget, Frédéric, Mouret-Reynier, Marie-Ange, Sohn, Joo Hyuk, Taylor, Donatienne, Harnden, Kathleen K, Khong, Hung, Kocsis, Judit, Dalenc, Florence, Dillon, Patrick M, Babu, Sunil, Waters, Simon, Deleu, Ines, García Sáenz, José A, Bria, Emilio, Cazzaniga, Marina, Lu, Janice, Aftimos, Philippe, Cortés, Javier, Liu, Shubin, Tonini, Giulia, Laurent, Dirk, Habboubi, Nassir, Conlan, Maureen G, Bardia, Aditya, Bidard, F, Kaklamani, V, Neven, P, Streich, G, Montero, A, Forget, F, Mouret-Reynier, M, Sohn, J, Taylor, D, Harnden, K, Khong, H, Kocsis, J, Dalenc, F, Dillon, P, Babu, S, Waters, S, Deleu, I, García Sáenz, J, Bria, E, Cazzaniga, M, Lu, J, Aftimos, P, Cortés, J, Liu, S, Tonini, G, Laurent, D, Habboubi, N, Conlan, M, Bardia, A, Bidard, Francois-Clement, Kaklamani, Virginia G, Neven, Patrick, Streich, Guillermo, Montero, Alberto J, Forget, Frédéric, Mouret-Reynier, Marie-Ange, Sohn, Joo Hyuk, Taylor, Donatienne, Harnden, Kathleen K, Khong, Hung, Kocsis, Judit, Dalenc, Florence, Dillon, Patrick M, Babu, Sunil, Waters, Simon, Deleu, Ines, García Sáenz, José A, Bria, Emilio, Cazzaniga, Marina, Lu, Janice, Aftimos, Philippe, Cortés, Javier, Liu, Shubin, Tonini, Giulia, Laurent, Dirk, Habboubi, Nassir, Conlan, Maureen G, and Bardia, Aditya

Abstract

PURPOSE Patients with pretreated estrogen receptor (ER)-positive/human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer have poor prognosis. Elacestrant is a novel, oral selective ER degrader that demonstrated activity in early studies.METHODSThis randomized, open-label, phase III trial enrolled patients with ER-positive/HER2-negative advanced breast cancer who had one-two lines of endocrine therapy, required pretreatment with a cyclin-dependent kinase 4/6 inhibitor, and ≤ 1 chemotherapy. Patients were randomly assigned to elacestrant 400 mg orally once daily or standard-of-care (SOC) endocrine monotherapy. Primary end points were progression-free survival (PFS) by blinded independent central review in all patients and patients with detectable ESR1 mutations.RESULTSPatients were randomly assigned to elacestrant (n = 239) or SOC (n = 238). ESR1 mutation was detected in 47.8% of patients, and 43.4% received two prior endocrine therapies. PFS was prolonged in all patients (hazard ratio = 0.70; 95% CI, 0.55 to 0.88; P =.002) and patients with ESR1 mutation (hazard ratio = 0.55; 95% CI, 0.39 to 0.77; P =.0005). Treatment-related grade 3/4 adverse events occurred in 7.2% receiving elacestrant and 3.1% receiving SOC. Treatment-related adverse events leading to treatment discontinuations were 3.4% in the elacestrant arm versus 0.9% in SOC. Nausea of any grade occurred in 35.0% receiving elacestrant and 18.8% receiving SOC (grade 3/4, 2.5% and 0.9%, respectively).CONCLUSIONElacestrant is the first oral selective ER degrader demonstrating a significant PFS improvement versus SOC both in the overall population and in patients with ESR1 mutations with manageable safety in a phase III trial for patients with ER-positive/HER2-negative advanced breast cancer.

Published
2022

23. Phase 2, randomized, double‐blind study of pracinostat in combination with azacitidine in patients with untreated, higher‐risk myelodysplastic syndromes

Author

Garcia‐Manero, Guillermo, Montalban‐Bravo, Guillermo, Berdeja, Jesus G., Abaza, Yasmin, Jabbour, Elias, Essell, James, Lyons, Roger M., Ravandi, Farhad, Maris, Michael, Heller, Brian, DeZern, Amy E., Babu, Sunil, Wright, David, Anz, Bertrand, Boccia, Ralph, Komrokji, Rami S., Kuriakose, Philip, Reeves, James, Sekeres, Mikkael A., Kantarjian, Hagop M., Ghalie, Richard, and Roboz, Gail J.

Published
2017
Full Text
View/download PDF

26. Phase Ib/II Study of Enzalutamide with Samotolisib (LY3023414) or Placebo in Patients with Metastatic Castration-Resistant Prostate Cancer

Author

Sweeney, Christopher J., primary, Percent, Ivor J., additional, Babu, Sunil, additional, Cultrera, Jennifer L., additional, Mehlhaff, Bryan A., additional, Goodman, Oscar B., additional, Morris, David S., additional, Schnadig, Ian D., additional, Albany, Costantine, additional, Shore, Neal D., additional, Sieber, Paul R., additional, Guba, Susan C., additional, Zhang, Wei, additional, Wacheck, Volker, additional, Donoho, Gregory P., additional, Szpurka, Anna M., additional, Callies, Sophie, additional, Lin, Boris Kin, additional, and Bendell, Johanna C., additional

Published
2022
Full Text
View/download PDF

27. Abstract GS2-02: Elacestrant, an oral selective estrogen receptor degrader (SERD), vs investigator’s choice of endocrine monotherapy for ER+/HER2- advanced/metastatic breast cancer (mBC) following progression on prior endocrine and CDK4/6 inhibitor therapy: Results of EMERALD phase 3 trial

Author

Bardia, Aditya, primary, Neven, Patrick, additional, Streich, Guillermo, additional, Montero, Alberto J., additional, Forget, Frédéric, additional, Mouret-Reynier, Marie-Ange, additional, Sohn, Joo Hyuk, additional, Vuylsteke, Peter, additional, Harnden, Kathleen K., additional, Khong, Hung, additional, Kocsis, Judit, additional, Dalenc, Florence, additional, Kaklamani, Virginia, additional, Dillon, Patrick, additional, Babu, Sunil, additional, Waters, Simon, additional, Deleu, Ines, additional, García-Sáenz, José, additional, Bria, Emilio, additional, Cazzaniga, Marina, additional, Lu, Janice, additional, Aftimos, Philippe, additional, Cortes, Javier, additional, Liu, Shubin, additional, Laurent, Dirk, additional, Conlan, Maureen G., additional, and Bidard, Francois-Clement, additional

Published
2022
Full Text
View/download PDF

29. Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax Combined with Hypomethylating Agents

Author

Pollyea, Daniel A., primary, Pratz, Keith W., additional, Wei, Andrew H., additional, Pullarkat, Vinod A., additional, Jonas, Brian A., additional, Recher, Christian, additional, Babu, Sunil, additional, Schuh, Andre C., additional, Dail, Monique, additional, Sun, Yan, additional, Potluri, Jalaja, additional, Chyla, Brenda, additional, and DiNardo, Courtney D., additional

Published
2021
Full Text
View/download PDF

32. ABCL-366: Mosunetuzumab (Mosun) Monotherapy for Elderly/Unfit Patients with First-Line Diffuse Large B-Cell Lymphoma (DLBCL) Continues to Show Promising Safety and Efficacy with Durable Complete Responses

Author

Olszewski, Adam, primary, Avigdor, Abraham, additional, Babu, Sunil, additional, Levi, Itai, additional, Eradat, Herbert, additional, Abadi, Uri, additional, Holmes, Houston, additional, McKinney, Matthew, additional, Woszczyk, Dariusz, additional, Giannopoulos, Krzysztof, additional, Jurczak, Wojciech, additional, McCord, Ron, additional, Xie, Yuying, additional, Zhou, Mingzhu, additional, Qayum, Naseer, additional, O’Hear, Carol, additional, Sellam, Gila, additional, and Horowitz, Netanel, additional

Published
2021
Full Text
View/download PDF

33. IBCL-203: Umbralisib, a PI3Kδ/CK1ε Dual Inhibitor Demonstrates Marked Clinical Activity in Patients with Relapsed or Refractory Indolent Non-Hodgkin Lymphoma (iNHL): Results from the Phase 2 Global UNITY-NHL Trial

Author

Ghosh, Nilanjan, primary, Zinzani, Pier Luigi, additional, Samaniego, Felipe, additional, Jurczak, Wojciech, additional, Derenzini, Enrico, additional, Reeves, James A., additional, Knopinska-Posluszny, Wanda, additional, Cheah, Chan Y., additional, Phillips, Tycel, additional, Lech-Maranda, Ewa, additional, Cheson, Bruce, additional, Calmi, Paolo, additional, Grosicki, Sebastian, additional, Leslie, Lori A., additional, Chavez, Julio C., additional, Fonseca, Gustavo, additional, Babu, Sunil, additional, Hodson, Daniel J., additional, Shao, Spencer H., additional, Burke, John M., additional, Sharman, Jeff P., additional, Law, Jennie Y., additional, Pagel, John M., additional, Miskin, Hari P., additional, Sportelli, Peter, additional, O’Connor, Owen A., additional, Weiss, Michael S., additional, and Fowler, Nathan H., additional

Published
2021
Full Text
View/download PDF

34. Poster: ABCL-366: Mosunetuzumab (Mosun) Monotherapy for Elderly/Unfit Patients with First-Line Diffuse Large B-Cell Lymphoma (DLBCL) Continues to Show Promising Safety and Efficacy with Durable Complete Responses

Author

Olszewski, Adam, primary, Avigdor, Abraham, additional, Babu, Sunil, additional, Levi, Itai, additional, Eradat, Herbert, additional, Abadi, Uri, additional, Holmes, Houston, additional, McKinney, Matthew, additional, Woszczyk, Dariusz, additional, Giannopoulos, Krzysztof, additional, Jurczak, Wojciech, additional, McCord, Ron, additional, Xie, Yuying, additional, Zhou, Mingzhu, additional, Qayum, Naseer, additional, O’Hear, Carol, additional, Sellam, Gila, additional, and Horowitz, Netanel, additional

Published
2021
Full Text
View/download PDF

35. Poster: IBCL-203: Umbralisib, a PI3Kδ/CK1ε Dual Inhibitor Demonstrates Marked Clinical Activity in Patients with Relapsed or Refractory Indolent Non-Hodgkin Lymphoma (iNHL): Results from the Phase 2 Global UNITY-NHL Trial

Author

Ghosh, Nilanjan, primary, Zinzani, Pier Luigi, additional, Samaniego, Felipe, additional, Jurczak, Wojciech, additional, Derenzini, Enrico, additional, Reeves, James A., additional, Knopinska-Posluszny, Wanda, additional, Cheah, Chan Y., additional, Phillips, Tycel, additional, Lech-Maranda, Ewa, additional, Cheson, Bruce, additional, Caimi, Paolo, additional, Grosicki, Sebastian, additional, Leslie, Lori A., additional, Chavez, Julio C., additional, Fonseca, Gustavo, additional, Babu, Sunil, additional, Hodson, Daniel J., additional, Shao, Spencer H., additional, Burke, John M., additional, Sharman, Jeff P., additional, Law, Jennie Y., additional, Pagel, John M., additional, Miskin, Hari P., additional, Sportelli, Peter, additional, O’Connor, Owen A., additional, Weiss, Michael S., additional, and Fowler, Nathan H., additional

Published
2021
Full Text
View/download PDF

36. Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma

Author

Olson, Daniel J., primary, Eroglu, Zeynep, additional, Brockstein, Bruce, additional, Poklepovic, Andrew S., additional, Bajaj, Madhuri, additional, Babu, Sunil, additional, Hallmeyer, Sigrun, additional, Velasco, Mario, additional, Lutzky, Jose, additional, Higgs, Emily, additional, Bao, Riyue, additional, Carll, Timothy C., additional, Labadie, Brian, additional, Krausz, Thomas, additional, Zha, Yuanyuan, additional, Karrison, Theodore, additional, Sondak, Vernon K., additional, Gajewski, Thomas F., additional, Khushalani, Nikhil I., additional, and Luke, Jason J., additional

Published
2021
Full Text
View/download PDF

38. Long-Term Efficacy and Safety of the Long-Acting Complement C5 Inhibitor Ravulizumab for the Treatment of Atypical Hemolytic Uremic Syndrome in Adults

Author

Barbour, Thomas, primary, Scully, Marie, additional, Ariceta, Gema, additional, Cataland, Spero, additional, Garlo, Katherine, additional, Heyne, Nils, additional, Luque, Yosu, additional, Menne, Jan, additional, Miyakawa, Yoshitaka, additional, Yoon, Sung-Soo, additional, Kavanagh, David, additional, Babu, Sunil, additional, Broeders, Nilufer, additional, Lietar, Nicole, additional, Brown, Fiona, additional, Campbell, Philip, additional, Campistol, Josep M., additional, Chowdhury, Paramit, additional, Kasimatis, Theo, additional, Cirami, Lino, additional, Caroti, Leonardo, additional, Antognoli, Guilia, additional, Delmas, Yahsou, additional, Dobronravov, Vladimir, additional, Gaeckler, Anja, additional, Garrouste, Cyril, additional, Greenwood, Gregory, additional, Griffin, Siân, additional, Huang, Chiu-Ching, additional, Chen, I-Ru, additional, Huang, Susan, additional, Kim, Jin Seok, additional, La Manna, Gaetano, additional, Le Quintrec, Moglie, additional, Jeantet, Guillaume, additional, Fumie, Iino, additional, Rondeau, Eric, additional, Haller, Hermann, additional, Morelle, Johan, additional, Goffin, Eric, additional, Muhlfeld, Anja, additional, Nagaraj, Shashi, additional, Arepally, Gowthami, additional, Oh, Doyeun, additional, Okumi, Masayoshi, additional, Terente, Manuel Praga, additional, Provot, Francois, additional, Schönermarck, Ulf, additional, Fischereder, Michael, additional, Terrada, Natalia Ramos, additional, Seitz-Polski, Barbara, additional, Favre, Guillaume, additional, Boyer-Suavet, Sonia, additional, Vinogradova, Maria, additional, Kirsanova, Tatiana, additional, and Wong, Edwin K.S., additional

Published
2021
Full Text
View/download PDF

39. Circulating tumor DNA (ctDNA) mutations may predict treatment response in extensive-stage small cell lung cancer (ES-SCLC) treated with talazoparib and temozolomide (TMZ).

Author

Mulroy, Matthew C, primary, Cummings, Amy Lauren, additional, Mendenhall, Melody A., additional, Kanamori, David E., additional, Nguyen, Andrew V., additional, Kim, David Dae-Young, additional, Lawler, William E., additional, Johnson, Tirrell T., additional, Tseng, Jennifer, additional, Babu, Sunil, additional, Brown, Andrew Bennett, additional, Dakhil, Shaker R., additional, Anand, Sidharth, additional, Wainberg, Zev A., additional, Slamon, Dennis J., additional, Garon, Edward B., additional, and Goldman, Jonathan Wade, additional

Published
2021
Full Text
View/download PDF

40. Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma

Author

Fowler, Nathan H., primary, Samaniego, Felipe, additional, Jurczak, Wojciech, additional, Ghosh, Nilanjan, additional, Derenzini, Enrico, additional, Reeves, James A., additional, Knopińska-Posłuszny, Wanda, additional, Cheah, Chan Y., additional, Phillips, Tycel, additional, Lech-Maranda, Ewa, additional, Cheson, Bruce D., additional, Caimi, Paolo F., additional, Grosicki, Sebastian, additional, Leslie, Lori A., additional, Chavez, Julio C., additional, Fonseca, Gustavo, additional, Babu, Sunil, additional, Hodson, Daniel J., additional, Shao, Spencer H., additional, Burke, John M., additional, Sharman, Jeff P., additional, Law, Jennie Y., additional, Pagel, John M., additional, Miskin, Hari P., additional, Sportelli, Peter, additional, O'Connor, Owen A., additional, Weiss, Michael S., additional, and Zinzani, Pier Luigi, additional

Published
2021
Full Text
View/download PDF

41. Corrigendum to “Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon S-S, Kavanagh D and Haller H; on behalf of the 311 Study Group. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment.” Kidney Int. 2020;97:1287–1296

Author

Rondeau, Eric, primary, Scully, Marie, additional, Ariceta, Gema, additional, Barbour, Tom, additional, Cataland, Spero, additional, Heyne, Nils, additional, Miyakawa, Yoshitaka, additional, Ortiz, Stephan, additional, Swenson, Eugene, additional, Vallee, Marc, additional, Yoon, Sung-Soo, additional, Kavanagh, David, additional, Haller, Hermann, additional, Babu, Sunil, additional, Broeders, Nilufer, additional, Lietar, Nicole, additional, Brown, Fiona, additional, Campbell, Philip, additional, Campistol, Josep M., additional, Blasco, Miquel, additional, Chowdhury, Paramit, additional, Kasimatis, Theo, additional, Cirami, Lino, additional, Caroti, Leonardo, additional, Antognoli, Guilia, additional, Delmas, Yahsou, additional, Dobronravov, Vladimir, additional, Gaeckler, Anja, additional, Garrouste, Cyril, additional, Greenwood, Gregory, additional, Griffin, Siân, additional, Huang, Chiu-Ching, additional, Chen, I-Ru, additional, Huang, Susan, additional, Kim, Jin Seok, additional, La Manna, Gaetano, additional, Comai, Giorgia, additional, Cappuccilli, Maria, additional, Le Quintrec, Moglie, additional, Jeantet, Guillaume, additional, Fumie, Iino, additional, Luque, Yosu, additional, Menne, Jan, additional, Morelle, Johan, additional, Goffin, Eric, additional, Muhlfeld, Anja, additional, Nagaraj, Shashi, additional, Arepally, Gowthami, additional, Oh, Doyeun, additional, Okumi, Masayoshi, additional, Terente, Manuel Praga, additional, Gutierréz, Elena, additional, Rodriguez, Paola, additional, Provot, Francois, additional, Schönermarck, Ulf, additional, Fischereder, Michael, additional, Terrada, Natalia Ramos, additional, Seitz-Polski, Barbara, additional, Favre, Guillaume, additional, Boyer-Suavet, Sonia, additional, Vinogradova, Maria, additional, Kirsanova, Tatiana, additional, and Wong, Edwin K.S., additional

Published
2021
Full Text
View/download PDF

43. Cytopenia Management in Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax Plus Azacitidine in the VIALE-A Study

Author

Pratz, Keith W., DiNardo, Courtney D., Selleslag, Dominik, Li, Junmin, Yamamoto, Kazuhito, Konopleva, Marina, McDonald, Andrew, Babu, Sunil, Stevens, Don A., Kantarjian, Hagop M., Traina, Fabiola, Venditti, Adriano, Mayer, Jiri, Montez, Melissa, Ramsingh, Giridharan, Jin, Huan, Ainsworth, William, Duan, Yinghui, Svensson, Anders Erik, Werner, Michael, Potluri, Jalaja, and Jonas, Brian A

Published
2020
Full Text
View/download PDF

45. Development and Evaluation of Active Case Detection Methods to Support Visceral Leishmaniasis Elimination in India

Author

Dubey, Pushkar, primary, Das, Aritra, additional, Priyamvada, Khushbu, additional, Bindroo, Joy, additional, Mahapatra, Tanmay, additional, Mishra, Prabhas Kumar, additional, Kumar, Ankur, additional, Franco, Ana O., additional, Rooj, Basab, additional, Sinha, Bikas, additional, Pradhan, Sreya, additional, Banerjee, Indranath, additional, Kumar, Manash, additional, Bano, Nasreen, additional, Kumar, Chandan, additional, Prasad, Chandan, additional, Chakraborty, Parna, additional, Kumar, Rakesh, additional, Kumar, Niraj, additional, Kumar, Aditya, additional, Singh, Abhishek Kumar, additional, Kundan, Kumar, additional, Babu, Sunil, additional, Shah, Hemant, additional, Karthick, Morchan, additional, Roy, Nupur, additional, Gill, Naresh Kumar, additional, Dwivedi, Shweta, additional, Chaudhuri, Indrajit, additional, Hightower, Allen W., additional, Chapman, Lloyd A C., additional, Singh, Chandramani, additional, Sharma, Madan Prasad, additional, Dhingra, Neeraj, additional, Bern, Caryn, additional, and Srikantiah, Sridhar, additional

Published
2021
Full Text
View/download PDF

46. Safety and efficacy outcomes with nivolumab plus ipilimumab in patients with advanced renal cell carcinoma and low Karnofsky performance status: Results from the CheckMate 920 trial.

Author

Hutson, Thomas E., primary, Carthon, Bradley Curtis, additional, Yorio, Jeffrey, additional, Babu, Sunil, additional, McKean, Heidi Ann, additional, Percent, Ivor John, additional, Tykodi, Scott S., additional, Harrison, Michael Roger, additional, Zhang, Joshua, additional, Zoco, Jesus, additional, Johansen, Jennifer L., additional, and George, Daniel J., additional

Published
2021
Full Text
View/download PDF

48. Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial

Author

Goldman, Jonathan W, primary, Dvorkin, Mikhail, additional, Chen, Yuanbin, additional, Reinmuth, Niels, additional, Hotta, Katsuyuki, additional, Trukhin, Dmytro, additional, Statsenko, Galina, additional, Hochmair, Maximilian J, additional, Özgüroğlu, Mustafa, additional, Ji, Jun Ho, additional, Garassino, Marina Chiara, additional, Voitko, Oleksandr, additional, Poltoratskiy, Artem, additional, Ponce, Santiago, additional, Verderame, Francesco, additional, Havel, Libor, additional, Bondarenko, Igor, additional, Każarnowicz, Andrzej, additional, Losonczy, György, additional, Conev, Nikolay V, additional, Armstrong, Jon, additional, Byrne, Natalie, additional, Thiyagarajah, Piruntha, additional, Jiang, Haiyi, additional, Paz-Ares, Luis, additional, Voitko, Nataliia, additional, Kazarnowicz, Andrzej, additional, Özgüroglu, Mustafa, additional, Conev, Nikolay, additional, Hochmair, Maximilian, additional, Burghuber, Otto, additional, Çiçin, Irfan, additional, Moiseenko, Vladimir, additional, Erman, Mustafa, additional, Kowalski, Dariusz, additional, Wojtukiewicz, Marek, additional, Adamchuk, Hryhoriy, additional, Vasilyev, Alexander, additional, Shevnia, Serhii, additional, Valev, Spartak, additional, Insa Molla, Maria Amelia, additional, Ursol, Grygorii, additional, Chiang, Anne, additional, Hartl, Sylvia, additional, Horváth, Zsolt, additional, Pajkos, Gábor, additional, Kim, Sang-We, additional, Smolin, Alexey, additional, Göksel, Tuncay, additional, Dakhil, Shaker, additional, Roubec, Jaromir, additional, Bogos, Krisztina, additional, Cornelissen, Robin, additional, Lee, Jong-Seok, additional, Garcia Campelo, Maria Rosario, additional, Lopez Brea, Marta, additional, Alacacioglu, Ahmet, additional, Casarini, Ignacio, additional, Ilieva, Rumyana, additional, Tonev, Ivan, additional, Somfay, Attila, additional, Bar, Jair, additional, Zer Kuch, Alona, additional, Minelli, Mauro, additional, Bartolucci, Roberta, additional, Roila, Fausto, additional, Saito, Haruhiro, additional, Azuma, Koichi, additional, Lee, Gyeong-Won, additional, Luft, Alexander, additional, Urda, Michal, additional, Delgado Mingorance, Juan Ignacio, additional, Majem Tarruella, Margarita, additional, Spigel, David, additional, Koynov, Krassimir, additional, Zemanova, Milada, additional, Panse, Jens, additional, Schulz, Christian, additional, Pápai Székely, Zsolt, additional, Sárosi, Veronika, additional, Delmonte, Angelo, additional, Bettini, Anna Cecilia, additional, Nishio, Makoto, additional, Okamoto, Isamu, additional, Hendriks, Lizza, additional, Mandziuk, Slawomir, additional, Lee, Yun Gyoo, additional, Vladimirova, Lyubov, additional, Isla Casado, Dolores, additional, Domine Gomez, Manuel, additional, Navarro Mendivil, Alejandro, additional, Morán Bueno, Teresa, additional, Wu, Shang-Yin, additional, Knoble, Jeanna, additional, Skrickova, Jana, additional, Venkova, Violetka, additional, Hilgers, Werner, additional, Laack, Eckart, additional, Bischoff, Helge, additional, Fülöp, Andrea, additional, Laczó, Ibolya, additional, Kósa, Judit, additional, Telekes, András, additional, Yoshida, Tatsuya, additional, Kanda, Shintaro, additional, Hida, Toyoaki, additional, Hayashi, Hidetoshi, additional, Maeda, Tadashi, additional, Kawamura, Tetsuji, additional, Nakahara, Yasuharu, additional, Claessens, Niels, additional, Lee, Ki Hyeong, additional, Chiu, Chao-Hua, additional, Lin, Sheng-Hao, additional, Li, Chien-Te, additional, Demirkazik, Ahmet, additional, Schaefer, Eric, additional, Nikolinakos, Petros, additional, Schneider, Jeffrey, additional, Babu, Sunil, additional, Lamprecht, Bernd, additional, Studnicka, Michael, additional, Fausto Nino Gorini, Carlos, additional, Kultan, Juraj, additional, Kolek, Vitezslav, additional, Souquet, Pierre-Jean, additional, Moro-Sibilot, Denis, additional, Gottfried, Maya, additional, Smit, Egbert, additional, Lee, Kyung Hee, additional, Kasan, Peter, additional, Chovanec, Jozef, additional, Goloborodko, Olexandr, additional, Kolesnik, Oleksii, additional, Ostapenko, Yuriy, additional, Lakhanpal, Shailendra, additional, Haque, Basir, additional, Chua, Winston, additional, Stilwill, Joseph, additional, Sena, Susana Noemi, additional, Girotto, Gustavo Colagiovanni, additional, De Marchi, Pedro Rafael Martins, additional, Martinelli de Oliveira, Fabricio Augusto, additional, Dos Reis, Pedro, additional, Krasteva, Rositsa, additional, Zhao, Yanqiu, additional, Chen, Chengshui, additional, Koubkova, Leona, additional, Robinet, Gilles, additional, Chouaid, Christos, additional, Grohe, Christian, additional, Alt, Jürgen, additional, Csánky, Eszter, additional, Somogyiné Ezer, Éva, additional, Heching, Norman Isaac, additional, Kim, Young Hak, additional, Aatagi, Shinji, additional, Kuyama, Shoichi, additional, Harada, Daijiro, additional, Nogami, Naoyuki, additional, Nokihara, Hiroshi, additional, Goto, Hisatsugu, additional, Staal van den Brekel, Agnes, additional, Cho, Eun Kyung, additional, Kim, Joo-Hang, additional, Ganea, Doina, additional, Ciuleanu, Tudor, additional, Popova, Ekaterina, additional, Sakaeva, Dina, additional, Stresko, Marian, additional, Demo, Pavol, additional, Godal, Robert, additional, Wei, Yu-Feng, additional, Chen, Yen-Hsun, additional, Hsia, Te-Chun, additional, Lee, Kang-Yun, additional, Chang, Huang-Chih, additional, Wang, Chin-Chou, additional, Dowlati, Afshin, additional, Sumey, Christopher, additional, Powell, Steven, additional, Goldman, Jonathan, additional, Zarba, Juan Jose, additional, Batagelj, Emilio, additional, Pastor, Andrea Viviana, additional, Zukin, Mauro, additional, Baldotto, Clarissa Serodio da Rocha, additional, Schlittler, Luis Alberto, additional, Calabrich, Aknar, additional, Sette, Claudia, additional, Dudov, Asen, additional, Zhou, Caicun, additional, Lena, Hervé, additional, Lang, Susanne, additional, Pápai, Zsuzsanna, additional, Goto, Koichi, additional, Umemura, Shigeki, additional, Kanazawa, Kenya, additional, Hara, Yu, additional, Shinoda, Masahiro, additional, Morise, Masahiro, additional, Hiltermann, Jeroen, additional, Mróz, Robert, additional, Ungureanu, Andrei, additional, Andrasina, Igor, additional, Chang, Gee-Chen, additional, Vynnychenko, Ihor, additional, Shparyk, Yaroslav, additional, Kryzhanivska, Anna, additional, Ross, Helen, additional, Mi, Kailhong, additional, Jamil, Rodney, additional, Williamson, Michael, additional, Spahr, Joseph, additional, Han, Zhigang, additional, Wang, Mengzhao, additional, Yang, Zhixiong, additional, Hu, Jie, additional, Li, Wei, additional, Zhao, Jun, additional, Feng, Jifeng, additional, Ma, Shenglin, additional, Zhou, Xiangdong, additional, Liang, Zongan, additional, Hu, Yi, additional, Chen, Yuan, additional, Bi, Minghong, additional, Shu, Yongqian, additional, Nan, Kejun, additional, Zhou, Jianying, additional, Zhang, Wei, additional, Ma, Rui, additional, Yang, Nong, additional, Lin, Zhong, additional, Wu, Gang, additional, Fang, Jian, additional, Zhang, Helong, additional, Wang, Kai, additional, and Chen, Zhendong, additional

Published
2021
Full Text
View/download PDF

49. Erratum to “Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon S-S, Kavanagh D, Haller H; on behalf of the 311 Study Group. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment” Kidney Int. 2020;97:1287–1296

Author

Rondeau, Eric, primary, Scully, Marie, additional, Ariceta, Gema, additional, Barbour, Tom, additional, Cataland, Spero, additional, Heyne, Nils, additional, Miyakawa, Yoshitaka, additional, Ortiz, Stephan, additional, Swenson, Eugene, additional, Vallee, Marc, additional, Yoon, Sung-Soo, additional, Kavanagh, David, additional, Haller, Hermann, additional, Babu, Sunil, additional, Broeders, Nilufer, additional, Lietar, Nicole, additional, Brown, Fiona, additional, Campbell, Philip, additional, Chowdhury, Paramit, additional, Kasimatis, Theo, additional, Cirami, Lino, additional, Caroti, Leonardo, additional, Antognoli, Guilia, additional, Delmas, Yahsou, additional, Dobronravov, Vladimir, additional, Gaeckler, Anja, additional, Garrouste, Cyril, additional, Greenwood, Gregory, additional, Griffin, Siân, additional, Huang, Chiu-Ching, additional, Chen, I-Ru, additional, Huang, Susan, additional, Kim, Jin Seok, additional, La Manna, Gaetano, additional, Comai, Giorgia, additional, Cappuccilli, Maria, additional, Le Quintrec, Moglie, additional, Jeantet, Guillaume, additional, Fumie, Iino, additional, Luque, Yosu, additional, Menne, Jan, additional, Morelle, Johan, additional, Goffin, Eric, additional, Muhlfeld, Anja, additional, Nagaraj, Shashi, additional, Arepally, Gowthami, additional, Oh, Doyeun, additional, Okumi, Masayoshi, additional, Terente, Manuel Praga, additional, Gutierréz, Elena, additional, Rodriguez, Paola, additional, Provot, Francois, additional, Schönermarck, Ulf, additional, Fischereder, Michael, additional, Terrada, Natalia Ramos, additional, Seitz-Polski, Barbara, additional, Favre, Guillaume, additional, Boyer-Suavet, Sonia, additional, Vinogradova, Maria, additional, Kirsanova, Tatiana, additional, and Wong, Edwin K.S., additional

Published
2020
Full Text
View/download PDF

50. Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: CheckMate 153

Author

Waterhouse, David M., primary, Garon, Edward B., additional, Chandler, Jason, additional, McCleod, Michael, additional, Hussein, Maen, additional, Jotte, Robert, additional, Horn, Leora, additional, Daniel, Davey B., additional, Keogh, George, additional, Creelan, Ben, additional, Einhorn, Lawrence H., additional, Baker, Justin, additional, Kasbari, Samer, additional, Nikolinakos, Petros, additional, Babu, Sunil, additional, Couture, Felix, additional, Leighl, Natasha B., additional, Reynolds, Craig, additional, Blumenschein, George, additional, Gunuganti, Vijay, additional, Li, Ang, additional, Aanur, Nivedita, additional, and Spigel, David R., additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results